Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

This Zacks Rank #3 (Hold) company’s shares have lost 80.7% in the year-to-date period against the industry’s 5.2% growth. The S&P 500 has increased 27.7% in the said time frame. The renowned ...

In the latest quarter, 11 analysts provided ratings for Nevro NVRO, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Albuterol sulfate 90mcg/inh; metered-dose aerosol (with a dose counter); CFC-free. Proair HFA (albuterol sulfate) Inhalation Aerosol is supplied as a pressurized aluminum canister with a red ...

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for Nevro ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...